GX BIO LABS · Product artwork
GLOW is a 70 mg blend of GHK-Cu, BPC-157 and TB-500. The linked studies provide component-level context rather than evidence for the combined formula.
10 available
View COA for 70 mg1 batch report available
Supplied formula: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg; total 70 mg. Declared catalogue specification; consult a matching batch report for measured results. TB-500 sequence and acetylation status remain unconfirmed; fragment and full-length thymosin beta-4 literature are not interchangeable.
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
1 report is available for this strength. Match the batch number on your supplied material.
View available COAsThe supplied GLOW formula combines GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, totalling 70 mg. Its ingredient literature spans collagen synthesis in fibroblasts, tendon-cell signalling and analytical identification of material sold as TB-500. These research topics do not establish the behaviour of the three ingredients together. In particular, a published identification of the Ac-LKKTETQ fragment in one TB-500 sample cannot confirm the sequence used in this blend or justify importing full-length thymosin beta-4 findings. The formula is the declared catalogue specification, while batch composition and finished-blend properties require their own evidence.
Supplied formula: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg; total 70 mg. Declared catalogue specification; consult a matching batch report for measured results. TB-500 sequence and acetylation status remain unconfirmed; fragment and full-length thymosin beta-4 literature are not interchangeable.
These papers concern individual ingredients, not the finished blend. Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
Fibroblast experiments measured collagen synthesis after GHK-Cu exposure. This is ingredient-level laboratory research; the investigators did not test the listed blend or a clinical skin outcome.
Read studyResearchers measured growth-hormone receptor expression and responses to growth hormone in tendon fibroblasts exposed to BPC-157. These cell experiments did not investigate this blend or demonstrate human tendon recovery.
Read studyMass spectrometry identified Ac-LKKTETQ in the tested TB-500 material. That finding does not confirm the sequence in this blend; the fragment is distinct from full-length thymosin beta-4, and the paper did not test efficacy.
Read studyGLOW is currently listed in 70 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
1 laboratory report is published for this compound. Match the selected strength and available batch identifiers, and open the original document to check the actual test scope.
The supplied formula is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500, totalling 70 mg. Ingredient studies do not establish the finished blend’s results. Check the original report for measured identity and quantities.
This listing combines CJC-1295 No DAC and ipamorelin at a stated 5 mg + 5 mg. The linked research concerns an individual component and does not test or validate the combined blend.
KLOW is an 80 mg blend of GHK-Cu, KPV, BPC-157 and TB-500. Its research context comes from separate ingredient studies; the combined formula has not been validated by the papers linked here.